Published in Vasc Cell on June 01, 2013
The macrophages in rheumatic diseases. J Inflamm Res (2016) 0.78
Anti-inflammatory activity of extracts of Bushen-Qiangdu-Zhilv decoction, a Chinese medicinal formula, in M1-polarized RAW264.7. BMC Complement Altern Med (2014) 0.77
Formation of microvascular networks: role of stromal interactions directing angiogenic growth. Microcirculation (2014) 0.76
Vascular endothelial growth factor levels in tears of patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol (2015) 0.75
Angiogenesis in alkaptonuria. J Inherit Metab Dis (2016) 0.75
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Mechanisms of angiogenesis. Nature (1997) 18.04
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity (2002) 8.19
Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol (1999) 7.66
The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 7.40
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest (2004) 5.59
Trophic macrophages in development and disease. Nat Rev Immunol (2009) 5.37
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med (1990) 3.93
A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane. Am J Pathol (1988) 3.72
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell (2003) 3.66
Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nat Immunol (2009) 3.60
Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum (2003) 3.29
During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med (1996) 3.18
Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A (2000) 3.16
Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol (2008) 3.13
Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol (2001) 3.08
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst (2003) 2.91
Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol (2006) 2.66
Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med (2004) 2.64
Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med (1994) 2.54
Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med (1991) 2.46
Local expression of interleukin-27 ameliorates collagen-induced arthritis. Arthritis Rheum (2011) 2.40
Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) (2004) 2.33
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30
TSG-6: a pluripotent inflammatory mediator? Biochem Soc Trans (2006) 2.20
Hypoxia regulates macrophage functions in inflammation. J Immunol (2005) 2.19
Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol (2000) 2.16
Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum (2003) 2.15
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest (2006) 2.10
TSG-6: a multifunctional protein associated with inflammation. J Cell Sci (2003) 1.97
Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature (2011) 1.91
Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J Immunol (1991) 1.88
Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum (2001) 1.87
Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum (2005) 1.79
Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum (2001) 1.71
Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis (2008) 1.70
The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol (2009) 1.65
Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol (1999) 1.62
Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res (2008) 1.61
Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol (2003) 1.58
IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol (2010) 1.57
Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest (1996) 1.54
Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther (2008) 1.52
Mechanisms of Disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol (2007) 1.48
Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum (1997) 1.44
Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest (1994) 1.44
Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res (1996) 1.43
Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.43
Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines. J Immunol (2009) 1.38
TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity. Cytokine Growth Factor Rev (1997) 1.37
Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol (2001) 1.36
Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol (2007) 1.30
Wnt/Frizzled signaling in the vasculature: new angiogenic factors in sight. Physiology (Bethesda) (2006) 1.30
Wnt5a induces endothelial inflammation via beta-catenin-independent signaling. J Immunol (2010) 1.30
Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford) (2006) 1.28
Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells. Am J Pathol (2003) 1.28
Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood (2006) 1.24
Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. Am J Pathol (2009) 1.23
Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther (2007) 1.23
Chemokines and angiogenesis. Curr Opin Rheumatol (2001) 1.20
The role of the vascular phase in solid tumor growth: a historical review. Neoplasia (1999) 1.20
Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther (2006) 1.19
Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum (1998) 1.19
Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum (2001) 1.15
Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol (1996) 1.13
IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways. J Immunol (2005) 1.12
Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther (2004) 1.09
Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva. Exp Eye Res (2004) 1.08
Cartilage-specific constitutive expression of TSG-6 protein (product of tumor necrosis factor alpha-stimulated gene 6) provides a chondroprotective, but not antiinflammatory, effect in antigen-induced arthritis. Arthritis Rheum (2002) 1.04
Angiogenesis in rheumatoid arthritis. Front Biosci (2005) 1.03
A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum (2002) 1.03
Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab (2006) 1.02
Macrophages in rheumatoid arthritis. Histol Histopathol (2007) 1.02
Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med (2002) 1.01
Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol (2004) 1.01
Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br J Pharmacol (2006) 0.99
Chemokines in rheumatic diseases. Curr Drug Targets (2006) 0.97
Integration of the beta-catenin-dependent Wnt pathway with integrin signaling through the adaptor molecule Grb2. PLoS One (2009) 0.95
Therapeutic inhibition of leukocyte recruitment in inflammatory diseases. Curr Opin Pharmacol (2004) 0.95
Pretreatment macrophage infiltration of the synovium predicts the clinical effect of both radiation synovectomy and intra-articular glucocorticoids. Ann Rheum Dis (2006) 0.92
Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet's patients with venous thrombosis. Clin Exp Rheumatol (2005) 0.91
Angiogenesis as an immunopharmacologic target in inflammation and cancer. Int Immunopharmacol (2004) 0.91
New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Int J Exp Pathol (1999) 0.91
Enhanced expression and DNA binding activity of two CCAAT/enhancer-binding protein isoforms, C/EBPbeta and C/EBPdelta, in rheumatoid synovium. Arthritis Rheum (2000) 0.89
Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Biomed Pharmacother (2006) 0.89
Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation (2002) 0.89
Role of macrophage CCAAT/enhancer binding protein delta in the pathogenesis of rheumatoid arthritis in collagen-induced arthritic mice. PLoS One (2012) 0.88
The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wien Med Wochenschr (2006) 0.86
Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem (2002) 0.84
Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Ann Rheum Dis (1999) 0.84
Relationship between interleukin-8 and neutrophil adhesion molecules in rheumatoid arthritis. Rheumatol Int (1996) 0.83
Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behçet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis. Rheumatol Int (2004) 0.82
Expression of platelet-derived growth factors C and D in the synovial membrane of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum (2006) 0.82
Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am (1995) 0.82
CC motif chemokine ligand 13 is associated with rheumatoid arthritis pathogenesis. Mod Rheumatol (2012) 0.80
Association of vascular endothelial growth factor gene polymorphisms with behcet disease in a Korean population. Hum Immunol (2005) 0.79
Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Behçet's disease. Anal Quant Cytol Histol (2006) 0.77
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28
Sonographic quantitative evaluation of scrotal veins in healthy subjects: normative values and implications for the diagnosis of varicocele. Eur Urol (2006) 2.17
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica (2003) 1.97
Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res (2007) 1.79
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res (2006) 1.72
Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica (2002) 1.69
Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J (2002) 1.61
Extra-skeletal effects of bisphosphonates. Joint Bone Spine (2006) 1.59
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem (2006) 1.59
Osteoblast physiology in normal and pathological conditions. Cell Tissue Res (2010) 1.49
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. Leuk Res (2007) 1.48
The role of podoplanin in tumor progression and metastasis. Anticancer Res (2008) 1.48
Angiogenesis in pre-malignant conditions. Eur J Cancer (2009) 1.45
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res (2003) 1.45
Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res (2004) 1.41
A portrait of Aristotle as an anatomist: historical article. Clin Anat (2007) 1.40
The adaptor protein p66Shc is a positive regulator in the angiogenic response induced by hypoxic T cells. J Leukoc Biol (2009) 1.40
Mondino de' Liuzzi and his Anothomia: a milestone in the development of modern anatomy. Clin Anat (2006) 1.38
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res (2006) 1.37
Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J (2002) 1.37
A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc Res (2004) 1.35
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst (2006) 1.32
Nerve growth factor as an angiogenic factor. Microvasc Res (2007) 1.32
Osteocalcin: skeletal and extra-skeletal effects. J Cell Physiol (2013) 1.31
Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol (2008) 1.30
Analysis of the role of chemokines in angiogenesis. J Immunol Methods (2003) 1.30
Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene. Mol Pharmacol (2005) 1.27
Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J Anat (2004) 1.22
Vitamin D and the immune system. J Rheumatol (2010) 1.22
The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol (2008) 1.21
Severe alterations of endothelial and glial cells in the blood-brain barrier of dystrophic mdx mice. Glia (2003) 1.21
Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res (2002) 1.16
Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin Cancer Res (2009) 1.16
Endothelial cells in the bone marrow of patients with multiple myeloma. Blood (2003) 1.15
HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A (2012) 1.15
Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res (2008) 1.14
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res (2011) 1.12
Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol (2005) 1.11
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res (2010) 1.09
Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol (2010) 1.09
Piecemeal degranulation as a general secretory mechanism? Anat Rec A Discov Mol Cell Evol Biol (2003) 1.09
Mast cells and angiogenesis in gastric carcinoma. Int J Exp Pathol (2010) 1.09
In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J (2001) 1.06
Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol (2011) 1.06
Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol (2005) 1.05
Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res (2007) 1.05
Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Clin Cancer Res (2012) 1.05
Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol (2009) 1.05
Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells. Br J Haematol (2003) 1.04
Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol (2005) 1.04
Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. Cancer Lett (2008) 1.04
Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J Allergy Clin Immunol (2009) 1.04
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood (2006) 1.04
Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A (2007) 1.03
Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol (2005) 1.03
Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol (2003) 1.00
Morphofunctional aspects of the blood-brain barrier. Curr Drug Metab (2012) 1.00
Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol (2005) 1.00
Long-term changes to in vitro preserved bioengineered human trachea and their implications for decellularized tissues. Biomaterials (2012) 1.00
Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem (2004) 0.99
The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep (2010) 0.99
Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res (2003) 0.98
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther (2005) 0.98
Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. Neoplasia (2009) 0.98
Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev (2008) 0.98
Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: involvement of the vascular endothelial growth factor receptor 2. Peptides (2008) 0.96
Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol (2006) 0.96
Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry (2002) 0.96
Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol Ther (2011) 0.96
Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release (2010) 0.96
The chick embryo chorioallantoic membrane as a model to study tumor metastasis. Angiogenesis (2008) 0.95
The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res (2009) 0.95
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer (2009) 0.95
Multiprofessional and intrahospital experience for diagnosis and treatment of pulmonary arterial hypertension. Monaldi Arch Chest Dis (2012) 0.95
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol (2007) 0.95
Endothelialization approaches for viable engineered tissues. Angiogenesis (2012) 0.94
Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol (2011) 0.94
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Mol Cancer Ther (2008) 0.94
The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis (2007) 0.94
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem (2010) 0.94
Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. Blood (2006) 0.94
Microvascular growth, development, and remodeling in the embryonic avian kidney: the interplay between sprouting and intussusceptive angiogenic mechanisms. Microsc Res Tech (2005) 0.94
Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene (2005) 0.93
Soul, mind, brain: Greek philosophy and the birth of neuroscience. Brain Res Bull (2006) 0.93
Osteoclastogenesis and arthritis. Clin Exp Med (2010) 0.93
The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy. Oncol Rep (2003) 0.93
Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood (2002) 0.93
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res (2010) 0.93
Myasthenia gravis and the thymus gland. A historical review. Clin Exp Med (2008) 0.93
Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol (2006) 0.93
Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol Cancer Ther (2005) 0.93
Chorioallantoic membrane for in vivo investigation of tissue-engineered construct biocompatibility. J Biomed Mater Res B Appl Biomater (2012) 0.93
Angiogenesis in multiple myeloma. Chem Immunol Allergy (2013) 0.93
HIF activation and VEGF overexpression are coupled with ZO-1 up-phosphorylation in the brain of dystrophic mdx mouse. Brain Pathol (2007) 0.92
Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathol Commun (2014) 0.92
Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood (2010) 0.92
Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its alpha receptor. Blood (2002) 0.91
Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov (2006) 0.91
Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma. Clin Cancer Res (2013) 0.91